The effect of sacubitril valsartan treatment in the early period of experimental autoimmune myocarditis model on mortality, morbidity, myocardial fibrosis parameters; animal study

Creative Commons License

Duygu A., Gazi E., Deveci B., Arslan M., Öztopuz R. Ö., Adalı Y.

ANATOLIAN JOURNAL OF CARDIOLOGY, vol.24, no.1, pp.120-121, 2020 (SCI-Expanded)

  • Publication Type: Article / Abstract
  • Volume: 24 Issue: 1
  • Publication Date: 2020
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CINAHL, EMBASE, MEDLINE, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.120-121
  • Çanakkale Onsekiz Mart University Affiliated: Yes


Background and Aim: The aim of this study is to see the effectiveness of early sacubitril-valsartan treatment in heart failure caused by myocarditis which is a common reason of non-ischemic dilated cardiomyopathy in young people by creating an experimental autoimmune myocarditis model. Methods: In the study, three groups were created by using a total of 18 rats. There were six wistar rats in each group and determined as EAM, EAM + Treatment and Control. The EAM model was created by giving an equal amount of porcine cardiac myosin and Complete Freund’s Adjuvant (CFA) to foot pad. No treatment was given to the EAM group. EAM + Treatment group received 20 mg/kg of sacubitril-valsartan twice daily from day 21 to day 42. No treatment was applied to the Control group. Histopathological, biochemical and PCR analysis were performed on the heart tissues taken after sacrification in 42nd day of study. Results: No significant difference was observed between EAM and EAM + Treatment group in congestion, fibrosis and cellular changes (p>0.05). No significant difference was observed between EAM and EAM + Treatment group at TNF α, TGF β1 levels (p>0.05). At IL 6 levels, there was no significant difference between the three groups (p>0.05). In pro BNP levels, no significant difference was observed between EAM and EAM + Treatment group (p=0.052). In the results of analysis other than IL 6, a significant difference was observed in both EAM and the EAM + Treatment group compared with the Control group (p<0.05). Conclusions: As a result of the examination analysis between the treatment group and the patient group, no significant difference between fibrosis, cytokine, BNP values was observed in the treatment group compaired with patient group although the values were lower in the treatment group. In the experimental models to be created in the future, it is thought that significant results can be obtained by giving high doses of drugs, using more animals or starting treatment earlier